Objective: The aim of the study was to evaluate influence of preoperative treatment with aspirin or heparin on platelet function and intensity of postoperative blood loss in early period after coronary artery bypass grafting (CABG).

Material And Methods: Study involved 75 patients (men) with ischemic heart disease, who underwent CABG. Patients were divided into three groups: aspirin pretreated (I group, n=25), heparin pretreated (II group, n=22) and III group (n=28) had no antiplatelet or anticoagulant pretreatment. At 24 h after surgery all patients started treatment with aspirin (ASS 100, Bayer), which lasted all hospitalization period. We have evaluated preoperative coagulation parameters: activated partial thromboplastin time, international normalized ratio, and fibrinogen level. Also we have compared platelet count, platelet aggregation induced by adenosine diphosphate during preoperative period, at 1 h, 20 h and at 7 day after surgery.

Results: Preoperative coagulation parameters were comparable in all groups. Platelet count was also similar. One hour after surgery platelet count remarkably decreased in all groups (p<0.001); at 20 hours after surgery changes remained the same and at 7 day a significant increase was observed in all groups (p<0.001). The lowest rate of preoperative platelet aggregation was found in I group (p<0.05). At 1 hour after surgery platelet aggregation decreased significantly in all groups, particularly in III group (p<0.001). At 20 hours after surgery platelet aggregation had a tendency to reach previous level and increased substantially in all groups. We have found more than 10% increase in platelet aggregation at 7 day compared to 20 hours postoperatively. These changes were observed in 32% (p<0.05), 27.3% (p<0.05) and 35.7% (p<0.001) of patients in the group I, II and III, respectively. Postoperative blood loss was significantly lowest in II group (p<0.01).

Conclusions: Our investigation shows that preoperative treatment with aspirin or heparin had no remarkable influence on dynamics of platelet function in early period after CABG. The least blood loss was observed in patients with heparin pretreatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

treatment aspirin
12
platelet count
12
preoperative treatment
8
aspirin heparin
8
heparin platelet
8
platelet function
8
function intensity
8
intensity postoperative
8
early period
8
period coronary
8

Similar Publications

Background: Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. The causes of tPA resistance, influenced by thrombus composition and timing, are not fully clear. Neutrophil extracellular traps (NETs), associated with poor outcomes and reperfusion resistance, contribute to thrombosis.

View Article and Find Full Text PDF

Importance: In the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial, anticoagulation did not prevent recurrent stroke among patients with a recent cryptogenic stroke and atrial cardiopathy. It is unknown whether anticoagulation prevents covert infarcts in this population.

Objective: To test the use of apixaban vs aspirin for prevention of nonlacunar covert infarcts after cryptogenic stroke in patients with atrial cardiopathy.

View Article and Find Full Text PDF

Essential Thrombocythemia: A Review.

JAMA

January 2025

CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.

Importance: Essential thrombocythemia, a clonal myeloproliferative neoplasm with excessive platelet production, is associated with an increased risk of thrombosis and bleeding. The annual incidence rate of essential thrombocythemia in the US is 1.5/100 000 persons.

View Article and Find Full Text PDF

Introduction: We investigated the subsequent trends in age and antithrombotic therapy in patients who underwent transurethral resection of bladder tumor (TURBT) and examined the rate of perioperative complications.

Methods: Medical records of patients who underwent TURBT were retrospectively analyzed. We arbitrarily divided the observation years into three periods (I: 2007-2013, II: 2014-2018, and III: 2019-2023) to compare the trends in age and frequency of perioperative complications after TURBT between patients taking and those not taking antithrombotic drugs.

View Article and Find Full Text PDF

Cardiovascular complications in chronic active Epstein-Barr virus disease: a case report and literature review.

Front Pediatr

January 2025

Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education (MOE), West China Institute of Women and Children's Health, Key Laboratory of Development and Diseases of Women and Children of Sichuan Province, Department of Pediatrics, Department of Pediatric Cardiology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.

Background: Cardiovascular involvement is a rare but severe complication of Epstein-Barr virus (EBV) infections. Patients with chronic active EBV (CAEBV) are at increased risk of developing cardiovascular complications and have a poor prognosis. Here, we report the rare case of a pediatric patient with CAEBV and EBV- hemophagocytic lymphohistiocytosis (HLH) complicated with a giant coronary artery aneurysm (CAA) and thrombosis, a giant Valsalva sinus aneurysm, and ascending aorta dilation seven years after the disease onset.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!